Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. 2008

Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu 520-2192, Japan. tutamoto@belle.shiga-med.ac.jp

BACKGROUND No previous study has compared the transcardiac gradient of norepinephrine (NE) and the prognosis of patients with chronic heart failure (CHF). OBJECTIVE To evaluate the prognostic role of the transcardiac gradient of NE in patients with CHF. METHODS We measured haemodynamic parameters and plasma levels of NE, brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) in the aortic root (AO) and coronary sinus (CS) in 356 consecutive patients with CHF. RESULTS During a median follow-up of 3.5 years, 40 patients died. Transcardiac gradients of BNP (273+/-276 vs. 472+/-433 pg/mL, p<0.0001), NT-proBNP (417+/-700 vs. 928+/-1093 pg/mL, p<0.0001) and NE (114+/-160 vs. 473+/-992 pg/mL, p<0.0001) were significantly higher in non-survivors than survivors. After adjustment for clinical variables associated with CHF including haemodynamics and neurohumoral factors, the transcardiac gradient of NE (p<0.0001) and plasma log NT-proBNP (p<0.0001) were independent prognostic predictors. Among 67 patients in whom 123I-metaiodobenzylguanidine (MIBG) could be performed, transcardiac increase in NE was correlated with the washout rate (r=0.398, p=0.0009) and was a superior predictor of mortality than MIBG parameters on stepwise multivariable Cox proportional hazards regression analyses. CONCLUSIONS The transcardiac increase in NE is an independent and useful prognostic predictor for evaluating the prognosis of CHF patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure

Related Publications

Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
September 1984, The New England journal of medicine,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
April 1981, The American journal of medicine,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
December 2004, Journal of the American College of Cardiology,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
March 1997, Circulation,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
December 2022, Revista espanola de cardiologia (English ed.),
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
March 2012, Chinese medical journal,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
January 2003, Journal of cardiovascular pharmacology,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
September 2000, Journal of the American College of Cardiology,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
May 2000, Circulation,
Takayoshi Tsutamoto, and Keizo Nishiyama, and Hiroshi Sakai, and Toshinari Tanaka, and Masanori Fujii, and Takashi Yamamoto, and Masayuki Yamaji, and Minoru Horie
January 2020, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Copied contents to your clipboard!